Adjuvant therapy for Stage IA uterine clear cell carcinoma with no myometrial invasion: a critical review of literature

Uterine clear cell carcinoma (UCC) is an aggressive variant of endometrial cancer. Comprehensive surgical staging is strongly recommended for these patients as an upstaging to Stage 3-4 occur in 35-50% of patients. Stage 1A (no myometrial invasion) according to FIGO 1988 staging system are seen very rarely in patients. In most of the studies, regarding adjuvant treatment, clear cell carcinoma were all evaluated with papillary serous carcinoma (PSC). Studies on clear cell histology are low in number and also a limited number of patients were included. Proportion of patients with complete surgical staging, number of lymph nodes excised, and rate of omentectomy were all heterogenous and were not presented uniformly in studies. There is no concensus regarding adjuvant treatment for Stage 1A patients. Some authors suggest only close observation. Vaginal brachytherapy is also strongly recommended in some studies of this review. Multi-institutional studies with homogenous patient characteristics with homogeneous surgery is warranted.

Uterine clear cell carcinoma; Adjuvant treatment; High grade endometrial cancer.

[1] Zorn K.K., Bonome T., Gangi L., Chandramuouli G.V., Awtrey C.S., Gardner G.J., et al.: ‘‘Gene expression profiles of serous, endometrioid and clear cell subtypes of ovarian and endometrial cancer’’. Clin. Cancer Res., 2005, 11, 6422.

[2] Risinger J.I., Maxwell G.L., Chandramouli G.V., Jazaeri A., Aprelikova O., Patterson T., et al.: ‘‘Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer’’. Cancer Res., 2003, 63, 6.

[3] Kwon J.S., Abrams J., Sugimoto A., Carey M.S.: ‘‘Is adjuvant therapy necessary for stage 1A nad 1B uterine papillary serous carcinoma and clear cell carcinoma after surgical staging’’. Int. J. Gynecol. Cancer, 2008, 18, 820.

[4] Aquino-Parsons C., Lim P., Wong F., Mildenberger M.: ‘‘Papillary serous and clear cell carcinoma limited to endometrial curettings in FIGO stage 1a and 1b endometrial adenocarcinoma:treatment implications’’. Gynecol. Oncol., 1998, 71, 83.

[5] Chang –Halpenny C.N., Natarajan S., Hwang-Grazino J.: ‘‘Early stage papillary serous or clear cell carcinoma confined to or involving an endometrial polyp:outcomes with and without adjuvant therapy’’. Gynecol. Oncol., 2013, 131, 598.

[6] Lajer H., Elnegaard S., Christensen R.D., Ortoft G.: ‘‘Survival after stage 1A endometrial cancer;can follow-up be altered? A prospective nationwide Danish Study’’. Acta Obstet. Gynecol. Scand., 2012, 91, 976.

[7] Thomas M.B., Mariani A., Wright J.D., Madarek E.O., Powell M.A., Mutch D.G., et al.: ‘‘Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma:a multi-institutional review’’. Gynecol Oncol 2008,108(2),293-97

[8] Kanbour-Shakir A., Tobon H.: ‘‘Primary clear cell carcinoma of the endometrium: a clinicopathologic study of 20 cases’’. Int. J. Gynecol. Pathol., 1991, 10, 67.

[9] Townamchai K., Berkowitz R., Bhagwat M., Damato A.L., Friesen S., Lee L.J., et al.: ‘‘Vaginal brachytherapy for early stage uterine papillary serous and cle,ar cell endometrial cancer’’. Gynecol. Oncol. 2013, 129,18.

[10] Creutzberg C.L., Van Putten W.L., Koper P.C., Lybeert M.L., Jobsen J.J., Warlam-Rodenhuis C.C., et al.: ‘‘Surgery and postoperative radiotherapy versus surgery alone for patients with stage 1 endometrial carcinoma:multicentre randomised trial’’. Lancet, 2000, 355, 1404.

[11] Cirisano F.D., Robboy S.J., Dodge R.K., Bentley R.C., Krigman H.R., Synan I.S., et al.: ‘‘The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma’’. Gynecol. Oncol. 2000, 77, 55.

[12] Sakuragi N., Hareyama H., Todo Y., Yamada H., Yamamoto R., Fujino T., et al.: ‘‘Prognostic significance of serous and clear cell adenocarcinoma in surgically staged endometrial carcinoma’’. Acta Obstet. Gynecol. Scand., 2000, 79,311.

[13] Saygili U., Kavaz S., Altunyurt S., Uslu T., Koyuncuoglu M., Erten O.: ‘‘Omentectomy, peritoneal biopsy and appendectomy in patients with clinical stage 1 endometrial carcinoma’’. Int. J. Gynecol. Cancer, 2001, 11, 471.

[14] Creasman W.T., Kohler M.F., Odicino F., Maisonneuve P., Boyle P.: ‘‘Prognosis of papillary serous, clear cell and grade 3 stage 1 carcinoma of the endometrium’’. Gynecol. Oncol., 2004, 95, 593.

[15] Carighead P.S., Sait K., Stuart G.C., Arthur K., Nation J., Duggan M., Guo D.: ‘‘Management of aggressive histologic variant of endometrial carcinoma at the Tom Baker Cancer centre between 1984 and 1994’’. Gynecol. Oncol., 2000, 77, 248.

[16] Abeler V.M., Vergote I.B., Kjorstad K.E., Trope CG. ‘‘Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern’’. Cancer, 1996, 78,1740.

[17] Smith R.S., Kapp D.S., Chen Q., Teng N.N.: ‘‘Treatment of high risk uterine cancer with whole abdominopelvic radiation therapy’’. Int. J. Radiat. Oncol. Biol. Phys., 2000, 8, 767.

[18] Cirisano F.D., Robboy J.S., Dodge R.K., Bentley R.C., Krigman H.R., Synan I.S., et al.: ‘‘Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma’’. Gynecol. Oncol. 1999, 74, 385.

[19] National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines): “Uterine neoplasms”. Version 1.2014. Available at : http://www.tri-kobe.org/nccn/guideline/gynecological/english/uterine.pdf

[20] Boren T., Miller D.S.: ‘‘Should all patients with serous and clear cell endometrial carcinoma receive adjuvant chemotherapy’?” Women’s Health, 2010, 6, 789.

[21] Trope C., Kristensen G.B., Abeler V.M.: ‘‘Clear-cell and papillary serous cancer:treatment options’’. Best Pract. Res. Clin. Obstet. Gynaecol., 2001, 15, 433.

[22] Vandenput I., Trovijk J., Vergote I., Moerman P., Leunen K., Berteloot P., et al.: ‘‘The role of adjuvant chemotherapy in surgical stages I-II serus and clear cell carcinomas and carcinosarcoma of the endometrium’’. Int J Gynecol Cancer, 2011, 21, 332.

[23] Batchelor E., Watkins J.M., Creasman W.T., Kohler M.F., Sinha D., Jenrette J.M.: ‘‘The role of radiotherapy in the management of resected uterine papillary serous and clear cell carcinoma’’. Eur. J. Obstet. Gynecol. Reprod. Biol., 2008, 141, 163.

[24] DuBeshter B., Estler K., Altobelli K., McDonald S., Glantz C., Angel C.: ‘‘High dose rate brachytherapy for stage I/II papillary serous or clear cell endometrial cancer’’. Gynecol. Oncol., 2004, 94, 383.